Across TCGA pan-cancer cohorts, ATP13A5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP13A5 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ATP13A5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ATP13A5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, UVM, and OV are the cancer types where ATP13A5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.966	0.621	.004	34	view →
UVM	DFS	Median	All	0.032	0.762	<.001	30	view →
OV	OS	Median	All	0.362	0.842	.005	18	view →
PRAD	DFS	Median	All	0.132	0.778	<.001	6	view →
SKCM	DFS	Median	III,IV	0.121	0.280	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ATP13A5 tumor-vs-normal RNA expression · all ATP13A5 data types